Importer of Controlled Substances Registration: Sharp Clinical Services, Inc., 27472-27473 [2016-10728]
Download as PDF
<![CDATA[
27472
Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension, without change, of a
currently approved collection.
2. The Title of the Form/Collection:
FFL Out of Business Records Request
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Form number: ATF F 5300.3A
Component: Bureau of Alcohol,
Tobacco, Firearms and Explosives, U.S.
Department of Justice.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Business or other for-profit.
Other (if applicable): None.
Abstract: The form is used by ATF to
notify licensees that go out of business
to send their firearms related business
records to the ATF, if the business
discontinuance is absolute, or to allow
the licensee to notify ATF of the
successor who will be maintaining
control of their firearms related records.
The questions are simple and a return
address is supplied. The format is easy
for the user to list the required
information ATF needs to perform its
functions in regard to the law.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: An estimated 2,745
respondents will take 5 minutes to
complete the survey.
6. An estimate of the total public
burden (in hours) associated with the
VerDate Sep<11>2014
17:20 May 05, 2016
Jkt 238001
collection: The estimated annual public
burden associated with this collection is
228.75 hours.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., Room 3E–
405B, Washington, DC 20530.
Dated: May 3, 2016.
Jerri Murray,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2016–10683 Filed 5–5–16; 8:45 am]
BILLING CODE 4410–FY–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Myoderm
ACTION:
Myoderm applied to be
registered as an importer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
(DEA) grants Myoderm registration as an
importer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated January 4, 2016, and published in
the Federal Register on January 11,
2016, 81 FR 1207, Myoderm, 48 East
Main Street, Norristown, Pennsylvania
19401 applied to be registered as an
importer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Myoderm to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of the following basic classes
of controlled substances:
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form for clinical trials, research,
and analytical purposes.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing,
research, and clinical trials. This
authorization does not extend to the
import of a finished FDA approved or
non-approved dosage form for
commercial sale.
Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–10727 Filed 5–5–16; 8:45 am]
BILLING CODE 4410–09–P
Notice of registration.
SUMMARY:
Controlled substance
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Sharp Clinical Services,
Inc.
ACTION:
Notice of registration.
Sharp Clinical Services, Inc.
applied to be registered as an importer
of a certain basic class of controlled
substance. The Drug Enforcement
Administration (DEA) grants Sharp
Clinical Services, Inc. registration as an
importer of this controlled substance.
SUPPLEMENTARY INFORMATION: By notice
dated January 4, 2016, and published in
the Federal Register on January 11,
2016, 81 FR 1207, Sharp Clinical
Services, Inc., 300 Kimberton Road,
Phoenixville, Pennsylvania 19460
applied to be registered as an importer
of a certain basic class of controlled
substance. No comments or objections
were submitted for this notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Sharp Clinical Services, Inc. to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
SUMMARY:
E:\FR\FM\06MYN1.SGM
06MYN1
Federal Register / Vol. 81, No. 88 / Friday, May 6, 2016 / Notices
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of marihuana (7360), a basic
class of controlled substance listed in
schedule I.
The company plans to import finished
pharmaceutical products containing
cannabis extracts in dosage form for
clinical trial studies.
This compound is listed under drug
code 7360. No other activity for this
drug code is authorized for this
registration. Approval of permits
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–10728 Filed 5–5–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: Noramco,
Inc.
ACTION:
Noramco, Inc. applied to be
registered as a manufacturer of certain
basic classes of controlled substances.
The Drug Enforcement Administration
(DEA) grants Noramco, Inc. registration
as a manufacturer of those controlled
substances.
SUMMARY:
By notice
dated November 23, 2015, and
published in the Federal Register on
December 3, 2015, 80 FR 75692,
Noramco, Inc., 500 Swedes Landing
Road, Wilmington, Delaware 19801–
4417 applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of Noramco, Inc. to
asabaliauskas on DSK3SPTVN1PROD with NOTICES
VerDate Sep<11>2014
17:20 May 05, 2016
Jkt 238001
Controlled substance
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the above-listed controlled substances
in bulk for distribution to its customers.
Notice of registration.
SUPPLEMENTARY INFORMATION:
manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the following basic
classes of controlled substances:
Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–10731 Filed 5–5–16; 8:45 am]
BILLING CODE 4410–09–P
27473
grants Almac Clinical Services Incorp
(ACSI) registration as an importer of this
controlled substance.
SUPPLEMENTARY INFORMATION: By notice
dated December 15, 2015, and
published in the Federal Register on
December 24, 2015, 80 FR 80387, Almac
Clinical Services Incorp (ACSI), 25 Fretz
Road, Souderton, Pennsylvania 18964
applied to be registered as an importer
of a certain basic class of controlled
substance. No comments or objections
were submitted for this notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Almac Clinical Services Incorp (ACSI)
to import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of Morphine (9300), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance in dosage
form for clinical trial only. Approval of
permit applications will occur only
when the registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–10730 Filed 5–5–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Drug Enforcement Administration
Importer of Controlled Substances
Registration: Almac Clinical Services
Incorp (ACSI)
[Docket No. DEA–392]
ACTION:
Notice of registration.
Almac Clinical Services
Incorp (ACSI) applied to be registered as
an importer of a certain basic class of
controlled substance. The Drug
Enforcement Administration (DEA)
SUMMARY:
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
Importer of Controlled Substances
Registration: Noramco, Inc.
ACTION:
Notice of registration.
Noramco, Inc. applied to be
registered as an importer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
SUMMARY:
E:\FR\FM\06MYN1.SGM
06MYN1
]]>Agencies
[Federal Register Volume 81, Number 88 (Friday, May 6, 2016)]
[Notices]
[Pages 27472-27473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-10728]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration: Sharp Clinical
Services, Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Sharp Clinical Services, Inc. applied to be registered as an
importer of a certain basic class of controlled substance. The Drug
Enforcement Administration (DEA) grants Sharp Clinical Services, Inc.
registration as an importer of this controlled substance.
SUPPLEMENTARY INFORMATION: By notice dated January 4, 2016, and
published in the Federal Register on January 11, 2016, 81 FR 1207,
Sharp Clinical Services, Inc., 300 Kimberton Road, Phoenixville,
Pennsylvania 19460 applied to be registered as an importer of a certain
basic class of controlled substance. No comments or objections were
submitted for this notice.
The DEA has considered the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the registration of Sharp Clinical Services,
Inc. to import the basic class of controlled substance is consistent
with the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971. The DEA investigated the company's
[[Page 27473]]
maintenance of effective controls against diversion by inspecting and
testing the company's physical security systems, verifying the
company's compliance with state and local laws, and reviewing the
company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above-named company is granted
registration as an importer of marihuana (7360), a basic class of
controlled substance listed in schedule I.
The company plans to import finished pharmaceutical products
containing cannabis extracts in dosage form for clinical trial studies.
This compound is listed under drug code 7360. No other activity for
this drug code is authorized for this registration. Approval of permits
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.
Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-10728 Filed 5-5-16; 8:45 am]
BILLING CODE 4410-09-P
